Lazertinib clinical trials

Explore recruiting lazertinib clinical trials.

Recruiting lazertinib studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lazertinib trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Hungary, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Germany, Spain, Finland, Greece, Portugal, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib

Germany, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Belgium, France, Italy, Spain, Poland, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI.

Italy, Netherlands, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Lazertinib trials by city

Lazertinib in Toronto Lazertinib in Vancouver Lazertinib in Montreal Lazertinib in Calgary Lazertinib in Edmonton Lazertinib in Ottawa Lazertinib in Winnipeg Lazertinib in Quebec City Lazertinib in Hamilton Lazertinib in Kitchener Lazertinib in London Lazertinib in Halifax Lazertinib in New York Lazertinib in Los Angeles Lazertinib in Chicago Lazertinib in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease